Patents by Inventor Michael A. Lynes

Michael A. Lynes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12583916
    Abstract: Provided are methods for use of an antibody, such as a monoclonal antibody and/or a humanized antibody, that binds to extracellular human metallothionein 1A (MT1A), or an antigenic binding fragment thereof, to improve glucose tolerance in a subject.
    Type: Grant
    Filed: July 24, 2023
    Date of Patent: March 24, 2026
    Assignees: UNIVERSITY OF CONNECTICUT, JOSLIN DIABETES CENTER, INC.
    Inventors: Michael A. Lynes, Yu-Hua Tseng, Matthew D. Lynes
  • Publication number: 20250306023
    Abstract: A method and system for predicting/diagnosing inflammatory diseases, such as, multisystem inflammatory syndrome in children (MIS-C), Kawasaki disease, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), respiratory syncytial virus, an adenovirus, influenza A, B C, or D, and/or parainfluenza in a subject is described.
    Type: Application
    Filed: March 28, 2025
    Publication date: October 2, 2025
    Inventors: Michele Maltz-Matyschsyk, Clare Melchiorre, Michael A. Lynes, Juan C. Salazar, David A. Lawrence, Aishwarya Jadhav, Katherine Herbst
  • Publication number: 20240067710
    Abstract: Disclosed herein are uses of inhibitor of extracellular human metallothionein (MT) to treat a disorder selected from the group consisting of diabetes, pre-diabetes, impaired glucose tolerance, hepatitis, and/or inflammatory liver disease, and compositions containing extracellular human MT.
    Type: Application
    Filed: October 27, 2023
    Publication date: February 29, 2024
    Inventors: Michael A. LYNES, Yu-Hua TSENG, Matthew D. LYNES
  • Publication number: 20240025981
    Abstract: Disclosed herein are uses of inhibitor of extracellular human metallothionein (MT) to treat a disorder selected from the group consisting of diabetes, pre-diabetes, impaired glucose tolerance, hepatitis, and/or inflammatory liver disease, and compositions containing extracellular human MT.
    Type: Application
    Filed: July 24, 2023
    Publication date: January 25, 2024
    Inventors: Michael A. LYNES, Yu-Hua TSENG, Matthew D. LYNES
  • Patent number: 11866488
    Abstract: Disclosed herein are compositions including an inhibitor of extracellular human metallothionein (MT) and a pancreatic targeting moiety linked to the inhibitor of extracellular human MT.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: January 9, 2024
    Assignees: UNIVERSITY OF CONNECTICUT, JOSLIN DIABETES CENTER, INC.
    Inventors: Michael A. Lynes, Yu-Hua Tseng, Matthew D. Lynes
  • Publication number: 20200369757
    Abstract: Disclosed herein are uses of inhibitor of extracellular human metallothionein (MT) to treat a disorder selected from the group consisting of diabetes, pre-diabetes, impaired glucose tolerance, hepatitis, and/or inflammatory liver disease, and compositions containing extracellular human MT.
    Type: Application
    Filed: January 17, 2019
    Publication date: November 26, 2020
    Inventors: Michael A. LYNES, Yu-Hua TSENG, Matthew D. LYNES
  • Patent number: 9353175
    Abstract: Metallothioneins are stress inducible proteins with modulating functions during inflammation. Antagonizing metallothioneins during gut inflammation reduces markers of inflammations and enhances recuperation of intestinal inflammation.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: May 31, 2016
    Assignees: UNIVERSITEIT GENT, UNIVERSITY OF CONNECTICUT
    Inventors: Martine De Vos, Debby Laukens, Lindsey DeVisscher, Michael A. Lynes
  • Publication number: 20150158940
    Abstract: Metallothioneins are stress inducible proteins with modulating functions during inflammation. Antagonizing metallothioneins during gut inflammation reduces markers of inflammations and enhances recuperation of intestinal inflammation.
    Type: Application
    Filed: December 23, 2014
    Publication date: June 11, 2015
    Inventors: Martine DE VOS, Debby LAUKENS, Lindsey DEVISSCHER, Michael A. LYNES
  • Publication number: 20140141009
    Abstract: Metallothioneins are stress inducible proteins with modulating functions during inflammation. Antagonizing metallothioneins during gut inflammation reduces markers of inflammations and enhances recuperation of intestinal inflammation.
    Type: Application
    Filed: July 9, 2012
    Publication date: May 22, 2014
    Applicant: Univeristy of Connecticut
    Inventors: Martine De Vos, Debby Laukens, Lindsey Devisscher, Michael A. Lynes
  • Patent number: 7655421
    Abstract: An assay technique for label-free, highly parallel, qualitative and quantitative detection of specific cell populations in a sample and for assessing cell functional status, cell-cell interactions and cellular responses to drugs, environmental toxins, bacteria, viruses and other factors that may affect cell function.
    Type: Grant
    Filed: June 16, 2006
    Date of Patent: February 2, 2010
    Assignee: Ciencia, Inc.
    Inventors: Michael A. Lynes, Salvador M. Fernández
  • Patent number: 6723523
    Abstract: As disclosed herein, the present invention is directed to a novel system for monitoring cell movement in response to chemotactic and chemokinetic factors. In this system, cells migrate in an under-agarose environment and their position is monitored using a system capable of measuring changes in impedance and other electrical parameters of the system at a target electrode lithographed onto a substrate as the cells arrive at the target. With the disclosed system, the time of arrival of cells at the target electrode is proportional to the dose of the chemoattractant species used to stimulate the cells and can be assessed by changes in resistance at the electrode. The system is readily able to distinguish between wild-type cells and mutants that are deficient in their chemotactic response. In addition, agents that interfere with chemotactic motility can be shown to lead to delayed arrival of cells at the target electrode.
    Type: Grant
    Filed: October 26, 2001
    Date of Patent: April 20, 2004
    Assignee: University of Connecticut
    Inventors: Michael A. Lynes, David A. Knecht
  • Publication number: 20030007973
    Abstract: Metallothionein is a stress response protein responsible for some forms of stress-related immunosuppression. An anti-metallothionein antibody can stimulate the humoral immune response to T-dependent antigens. An anti-metallothionein antibody is particularly useful when administered with an antigen to stimulate the immune response in a subject. An anti-metallothionein antibody can be administered to a subject with a vaccine to immunize the subject.
    Type: Application
    Filed: June 24, 2002
    Publication date: January 9, 2003
    Inventor: Michael A. Lynes
  • Publication number: 20020086280
    Abstract: As disclosed herein, the present invention is directed to a novel system for monitoring cell movement in response to chemotactic and chemokinetic factors. In this system, cells migrate in an under-agarose environment and their position is monitored using a system capable of measuring changes in impedance and other electrical parameters of the system at a target electrode lithographed onto a substrate as the cells arrive at the target. With the disclosed system, the time of arrival of cells at the target electrode is proportional to the dose of the chemoattractant species used to stimulate the cells and can be assessed by changes in resistance at the electrode. The system is readily able to distinguish between wild-type cells and mutants that are deficient in their chemotactic response. In addition, agents that interfere with chemotactic motility can be shown to lead to delayed arrival of cells at the target electrode.
    Type: Application
    Filed: October 26, 2001
    Publication date: July 4, 2002
    Inventors: Michael A. Lynes, David A. Knecht